Lupin Limited (BSE: 500257, NSE: LUPIN) and Tenpoint Therapeutics Holding Limited have announced an exclusive licensing agreement granting Lupin's European specialty ophthalmology subsidiary VISUfarma B.V. the rights to commercialize carbachol and brimonidine tartrate ophthalmic solution (Yuvezzi) 2.75%/0.1% across the EU, UK, Switzerland, Norway, and Iceland.
The deal gives VISUfarma responsibility for regulatory activities, marketing, distribution, and sale in those territories, while Tenpoint's US subsidiary Visus Therapeutics retains rights for the US and the rest of the world. The total potential value reaches up to EUR 75 million (approximately USD 83 million), comprising a EUR 20 million equity investment from VISUfarma into Visus and up to EUR 55 million in regulatory and commercial milestone payments, plus tiered royalties on net sales for the duration of each country's license term, which runs to the 20th anniversary of first commercial sale per country.
Yuvezzi is a once-daily, fixed-dose combination ophthalmic solution combining carbachol, a muscarinic receptor agonist that induces pupil constriction, and brimonidine tartrate, an alpha-2 adrenergic receptor agonist that modulates iris dilation. Together they create a sustained pinhole effect that improves near visual acuity in adults with presbyopia.
The agreement builds directly on Lupin's April 2026 acquisition of VISUfarma from GHO Capital Partners, which gave the company a European specialty ophthalmology platform with more than 60 branded products spanning dry eye, glaucoma, and retinal health. Tenpoint had already submitted a Marketing Authorization Application for Yuvezzi to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) via the International Recognition Procedure in July 2026, ahead of the current deal closing.